# Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

> **NCT03575871** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 391 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** PF-04965842 100 mg
- **DRUG:** PF-04965842 200 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03575871
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-29
- **Primary completion:** 2019-08-13
- **Final completion:** 2019-08-13
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575871, "Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03575871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*